[
  {
    "ts": null,
    "headline": "Gilead’s HIV Breakthrough",
    "summary": "Gilead’s HIV Breakthrough",
    "url": "https://finnhub.io/api/news?id=fcfa8a9f6c204dd334a18707ca3d6f69fd168452caf261995bec789b89a41bc0",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750701900,
      "headline": "Gilead’s HIV Breakthrough",
      "id": 135501260,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead’s HIV Breakthrough",
      "url": "https://finnhub.io/api/news?id=fcfa8a9f6c204dd334a18707ca3d6f69fd168452caf261995bec789b89a41bc0"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=5b49f3331e871eea980223af0a74e90353643b485e6fba93872ae0942f81ee0e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750696560,
      "headline": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "id": 135501280,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=5b49f3331e871eea980223af0a74e90353643b485e6fba93872ae0942f81ee0e"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=57f3adf4392d6966692dcd584363cfea6e4c58752a23ed4b3e0b7f702402a4de",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750686003,
      "headline": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 135481845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=57f3adf4392d6966692dcd584363cfea6e4c58752a23ed4b3e0b7f702402a4de"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : Czech Republic Methodological Note 2024 (in English) (gilead sciences czech republic methodological note 2024 in english)",
    "summary": "Methodological Note Contents Introduction 2 Definition of Transfers of Value 2 ...",
    "url": "https://finnhub.io/api/news?id=ae800c32273a4dda1c7a926042f68b6bad6aca8952f97adb8086bb811d5054da",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750670168,
      "headline": "Gilead Sciences : Czech Republic Methodological Note 2024 (in English) (gilead sciences czech republic methodological note 2024 in english)",
      "id": 135475103,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Methodological Note Contents Introduction 2 Definition of Transfers of Value 2 ...",
      "url": "https://finnhub.io/api/news?id=ae800c32273a4dda1c7a926042f68b6bad6aca8952f97adb8086bb811d5054da"
    }
  },
  {
    "ts": null,
    "headline": "5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call",
    "summary": "Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the quarter’s outcomes to growth in the HIV and liver disease businesses, with Biktarvy and Descovy showing strong demand. However, softness in oncology—particularly Trodelvy—and ongoing challenges in the cell therapy segment weighed on overall results. CEO Daniel O’Day acknowledged, “Year-over-year g",
    "url": "https://finnhub.io/api/news?id=59ca1649fbda2ccf7229685717be1d60000582ab770749abd3f4f1af52092458",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750648932,
      "headline": "5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call",
      "id": 135481846,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the quarter’s outcomes to growth in the HIV and liver disease businesses, with Biktarvy and Descovy showing strong demand. However, softness in oncology—particularly Trodelvy—and ongoing challenges in the cell therapy segment weighed on overall results. CEO Daniel O’Day acknowledged, “Year-over-year g",
      "url": "https://finnhub.io/api/news?id=59ca1649fbda2ccf7229685717be1d60000582ab770749abd3f4f1af52092458"
    }
  }
]